Nothing Special   »   [go: up one dir, main page]

AR107786A1 - Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal - Google Patents

Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal

Info

Publication number
AR107786A1
AR107786A1 ARP170100523A ARP170100523A AR107786A1 AR 107786 A1 AR107786 A1 AR 107786A1 AR P170100523 A ARP170100523 A AR P170100523A AR P170100523 A ARP170100523 A AR P170100523A AR 107786 A1 AR107786 A1 AR 107786A1
Authority
AR
Argentina
Prior art keywords
disease
detection
methods
compositions
diagnosis
Prior art date
Application number
ARP170100523A
Other languages
English (en)
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of AR107786A1 publication Critical patent/AR107786A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/348—Urinary tract infections
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

La divulgación proporciona composiciones y métodos para la detección de enfermedad renal y enfermedad periodontal en mamíferos.
ARP170100523A 2016-03-02 2017-03-02 Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal AR107786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662302299P 2016-03-02 2016-03-02

Publications (1)

Publication Number Publication Date
AR107786A1 true AR107786A1 (es) 2018-06-06

Family

ID=58410448

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100523A AR107786A1 (es) 2016-03-02 2017-03-02 Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal

Country Status (16)

Country Link
US (2) US10725052B2 (es)
EP (2) EP4299586A3 (es)
JP (3) JP7187317B2 (es)
KR (2) KR102424496B1 (es)
CN (1) CN108700600B (es)
AR (1) AR107786A1 (es)
AU (1) AU2017225758B2 (es)
BR (1) BR112018067292A2 (es)
CA (1) CA3016163A1 (es)
DK (1) DK3423838T5 (es)
ES (1) ES2970868T3 (es)
MX (2) MX2018010536A (es)
NZ (1) NZ745263A (es)
TW (1) TWI822655B (es)
WO (1) WO2017151871A1 (es)
ZA (1) ZA201806418B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI822655B (zh) * 2016-03-02 2023-11-21 美商英代斯實驗公司 用於檢測及診斷腎臟疾病及牙周病之方法及組合物
CN111033637B (zh) 2017-08-08 2023-12-05 费森尤斯医疗保健控股公司 用于治疗和评估慢性肾脏疾病的进程的系统和方法
JP7207585B2 (ja) * 2017-09-01 2023-01-18 株式会社三洋物産 遊技機
CN110938130B (zh) * 2019-11-08 2021-07-09 上海交通大学 一种生物活性多肽rvfqplphenkpltl及其制备方法和应用
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
NL1020962C2 (nl) 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US20070087448A1 (en) 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
AU2006207954A1 (en) * 2005-01-28 2006-08-03 Childrens Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
CA2596469A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CN101120904B (zh) 2006-11-13 2011-06-29 李复生 癌症疾病治疗器
US9000134B2 (en) 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
EP2346525A4 (en) * 2008-10-02 2012-05-09 Celtaxsys Inc METHODS OF MODULATION OF NEGATIVE CHIMOTAXIA OF IMMUNE CELLS
US20110287964A1 (en) 2008-11-17 2011-11-24 The Brigham And Women's Hospital, Inc. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans
US9476868B2 (en) * 2009-12-23 2016-10-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
KR101222437B1 (ko) * 2010-03-17 2013-01-15 경북대학교 산학협력단 바이오마커
CA2799536C (en) * 2010-06-03 2020-03-10 Idexx Laboratories, Inc. Markers for renal disease
CN101937000A (zh) * 2010-08-05 2011-01-05 北京倍爱康生物技术有限公司 一种人胱抑素c的磁微粒分离化学发光免疫分析检测方法
TWI822655B (zh) * 2016-03-02 2023-11-21 美商英代斯實驗公司 用於檢測及診斷腎臟疾病及牙周病之方法及組合物

Also Published As

Publication number Publication date
JP2022028790A (ja) 2022-02-16
US10725052B2 (en) 2020-07-28
NZ745263A (en) 2022-07-01
ZA201806418B (en) 2019-07-31
WO2017151871A1 (en) 2017-09-08
JP2024028816A (ja) 2024-03-05
BR112018067292A2 (pt) 2019-01-02
EP3423838A1 (en) 2019-01-09
US20200400683A1 (en) 2020-12-24
JP7187317B2 (ja) 2022-12-12
KR20210127763A (ko) 2021-10-22
JP2019508694A (ja) 2019-03-28
DK3423838T5 (da) 2024-09-16
US20170269101A1 (en) 2017-09-21
ES2970868T3 (es) 2024-05-31
CN108700600A (zh) 2018-10-23
EP3423838B1 (en) 2023-11-08
CN108700600B (zh) 2022-06-03
MX2023012628A (es) 2023-11-08
DK3423838T3 (da) 2024-02-05
AU2017225758B2 (en) 2023-03-16
KR102311590B1 (ko) 2021-10-12
EP4299586A2 (en) 2024-01-03
TWI822655B (zh) 2023-11-21
EP4299586A3 (en) 2024-04-03
CA3016163A1 (en) 2017-09-08
MX2018010536A (es) 2018-11-09
KR20180114936A (ko) 2018-10-19
AU2017225758A1 (en) 2018-08-30
KR102424496B1 (ko) 2022-07-25
TW201736850A (zh) 2017-10-16

Similar Documents

Publication Publication Date Title
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MD3240554T2 (ro) Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MD3204024T2 (ro) Compoziții care conțin tulpini bacteriene
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MD3549592T2 (ro) Compoziții care conţin tulpini bacteriene
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
EA201691991A1 (ru) Мультиспецифические антитела
UY34763A (es) Inhibidores de la agregación plaquetaria
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων